News and Trends 26 May 2016
French T-cell Expert restarts trial for Crohn’s after Manufacturing Hiccup
TxCell is restarting its trial for Ovasave, an autologous T-cell therapy, with a new manufacturing partner. This therapy is targeting Crohn’s disease which does not respond to current treatments. TxCell is based in Sophia-Antipolis (France) and is developing immunotherapies based on a type of T-cells that have anti-inflammatory properties – regulatory T-lymphocytes (Tregs). Its most advanced programme is in refractory Crohn’s […]